Caladrius reports interim Phase II data for Type I diabetes candidate

Caladrius Biosciences Inc. (NASDAQ:CLBS) said recent-onset Type I diabetes candidate CLBS03 was "non-futile as determined by predefined futility criteria for therapeutic effect" in

Read the full 232 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE